Commenced in January 2007
Frequency: Monthly
Edition: International
Paper Count: 30820
ISTER (Immune System - Tumor Efficiency Rate): An Important Key for Planning in Radiotherapic Facilities

Authors: O. Sotolongo-Grau, D. Rodriguez-Perez, J. A. Santos-Miranda, M. M. Desco, O. Sotolongo-Costa, J. C. Antoranz


The use of the oncologic index ISTER allows for a more effective planning of the radiotherapic facilities in the hospitals. Any change in the radiotherapy treatment, due to unexpected stops, may be adapted by recalculating the doses to the new treatment duration while keeping the optimal prognosis. The results obtained in a simulation model on millions of patients allow the definition of optimal success probability algorithms.

Keywords: Radiation Oncology, mathematical model, dynamical systems applications

Digital Object Identifier (DOI):

Procedia APA BibTeX Chicago EndNote Harvard JSON MLA RIS XML ISO 690 PDF Downloads 1106


[1] VA Kuznetsov, I Makalkin, MA Taylor, and AS Perelson. Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis. Bull Math Biology, 56:295-321, 1994.
[2] RK Sachs and LR Hlatky. Simple ode models of tumor growth and antiangiogenic or radiation treatment. Math. Comp. Modelling, 33:1297- 1305, 2001.
[3] Galach M. Dynamics of the tumor-immune system competition - the effect of time delay. Int J Appl Math Comput Sci, 13:395-406, 2003.
[4] H Enderling, RA Alexander, and AJ Mark. Mathematical modelling of radiotherapy strategies for early breast cancer. Journal of Theoretical Biology, 241:158-171, 2006.
[5] O Sotolongo-Costa and et al. Behavior of tumors under nonstationary therapy. Physica D, 178:242-253, 2003.
[6] D Dingli, MD Cascino, K Josic, SJ Russell, and Z Bajzer. Mathematical modeling of cancer radiovirotherapy. Mathematical Biosciences, 199:55-78, 2006.
[7] O Sotolongo-Grau, D Rodriguez Perez, JA Santos Miranda, O Sotolongo-Costa, and JC Antoranz. Immune system-tumour efficiency ratio as a new oncological index for radiotherapy treatment optimization. Math Med Biol, 26(4):297-307, 2009.
[8] A d-Onofrio. A general framework for modeling tumor-inmune system competition and immunotherapy: Mathematical analysis and biomedical inferences. Physica D, 208:220-235, 2005.
[9] A Matzavinos, M Chaplain, and V Kuznetsov. Mathematical modelling of the spatio-temporal response of cytotoxic t-lymphocytes to a solid tumour. Math Med Biol, 21:1-34, 2004.
[10] A Matzavinos and M Chaplain. Travelling wave analysis of a model of the immune response to cancer. C. R. Biologies, 327:995-1008, 2004.
[11] D Kirschner and J Panetta. Modelling immunotherapy of the tumorimmune system interaction. J. Math. Biol., 38:235-252, 1998.
[12] L de Pillis, AE Radunskaya, and CL Wiseman. A validated mathematical model of cell-mediated immune response to tumor growth. Cancer Research, 65:7950-7958, 2005.
[13] VS Khoo. Radiotherapeutic techniques for prostate cancer, dose escalation and brachytherapy. Clinical Oncology, 17:560-571, 2005.
[14] O. Sotolongo-Grau, D. Rodriguez-Perez, J. A. Santos-Miranda, M. M. Desco, O. Sotolongo-Costa, and J. C. Antoranz. A mathematical aid decision tool for rt planning. In O. D ossel and W.C. Schlegel, editors, WC 2009, IFMBE Proceedings 25 I, pages 101-104, 2009.
[15] WJ Mackillop. Killing time: The consequences of delays in radiotherapy. Radiotherapy and Oncology, 84:1 - 4, 2007.
[16] AR Jensen, HM Nellemann, and J Overgaard. Tumor progression in waiting time for radiotherapy in head and neck cancer. Radiotherapy and Oncology, 84:5-10, 2007.
[17] TL Whiteside. Apoptosis of immune cells in the tumor microenvironment and peripheral circulation of patients with cancer: implications for immunotherapy. Vaccine, 20:A46-A51, 2002.
[18] TL Whiteside. Immune suppression in cancer: Effects on immune cells, mechanisms and future therapeutic intervention. Seminars in Cancer Biology, 16:3-15, 2006.
[19] D Rodriguez-Perez, O Sotolongo-Grau, R Espinosa Riquelme, O Sotolongo-Costa, JA Santos Miranda, and JC Antoranz. Assesment of cancer immunotherapy aoutcome in terms of the immune response time features. Math Med Biol, 24:287-300, 2007.
[20] S Sundstrom, R Bremnes, U Aasebo, S Aamdal, R Htlevoll, P Brunsvig, DC Johannessen, O Klepp, PM Fayers, and Kaasa S. Hypofractioned palliative radiotherapy (17 Gy per two fractions) in advanced non-smallcell lung carcinoma is comparable to standard fractionation for symptom control and survival: A national phase III trial. Journal of Clinical Oncology, 22:801-810, 2004.
[21] GG Steel. Basic Clinical Radiobiology for Radiation Oncologists. Edward Arnold Publishers, London, 1993.
[22] D Rades and S Lang. Prognostic value of haemoglobin levels during concurrent radio-chemotherapy in the treatment of oesophageal cancer. Clinical Oncology, 18:139-144, 2006.
[23] A Martin and SA Harbison. An introduction to radiation protection. London, Chapman and Hall, 1998.
[24] P Mayles, A Nahum, and JC Rosenwald. Handbook of radiotherapy physics. Taylor & Francis, London, 2007.